J.P. Morgan Day 1: Companies Make Deal-Making, COVID-19 Promises
Updates From Amgen, Gilead, Alnylam, Vertex, BioNTech, BioMarin, Merck KGAA
Executive Summary
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Business development is key topic for Amgen and Vertex; BioNTech talks COVID-19 vaccine supply while Merck KGAA's new CEO pledges to rise to meet the challenges posed by COVID-19.
You may also be interested in...
Amgen Eschews Some Of Its BiTEs, But Otezla Spurs Growth
Without Otezla’s $2.2bn in 2020 sales, Amgen’s full-year revenue would have been slightly lower than in 2019, which is why all eyes are on the company’s R&D programs and near-term approvals.
While Amgen Sees Success For Two Growth Drivers, Headwinds Remain
Scrip discussed key wins for sotorasib in lung cancer and tezepelumab in asthma with Amgen executives Murdo Gordon and David Reese, but COVID-19 and other challenges are looming.
Quick Listen: Scrip’s Five Must-Know Things
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.